Corrigendum to “Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial” [Eur. Urol. 86(2) (2024) 90–94]

IF 25.3 1区 医学 Q1 UROLOGY & NEPHROLOGY European urology Pub Date : 2025-01-01 DOI:10.1016/j.eururo.2024.10.002
Kelly N. Fitzgerald , Chung-Han Lee , Martin H. Voss , Maria I. Carlo , Andrea Knezevic , Laura Peralta , Yingbei Chen , Robert A. Lefkowitz , Neil J. Shah , Colette N. Owens , Deaglan J. McHugh , David H. Aggen , Andrew L. Laccetti , Ritesh R. Kotecha , Darren R. Feldman , Robert J. Motzer
{"title":"Corrigendum to “Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial” [Eur. Urol. 86(2) (2024) 90–94]","authors":"Kelly N. Fitzgerald , Chung-Han Lee , Martin H. Voss , Maria I. Carlo , Andrea Knezevic , Laura Peralta , Yingbei Chen , Robert A. Lefkowitz , Neil J. Shah , Colette N. Owens , Deaglan J. McHugh , David H. Aggen , Andrew L. Laccetti , Ritesh R. Kotecha , Darren R. Feldman , Robert J. Motzer","doi":"10.1016/j.eururo.2024.10.002","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Page 96"},"PeriodicalIF":25.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0302283824026435","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cabozantinib加Nivolumab治疗非透明细胞肾细胞癌患者:II期试验的最新结果》更正 [Eur. Urol. 86(2) (2024) 90-94]
作者感到遗憾的是,文中对不良事件(AE)发生率的估计值有四处错误,与相应表格中的正确估计值不符。具体而言,文中对以下治疗相关不良事件发生率的估计值有误:1)任何级别的不良事件;2)3-4 级不良事件;3)3-4 级 AST 事件;4)3-4 级 ALT 事件。正确值已列入相应的补充表 2 和表 4,并在此予以说明:40名患者(100%)发生了任何级别的治疗相关不良反应;20名患者(50%)发生了3-4级不良反应。治疗相关的 3-4 级 AST 和 ALT 升高分别为 13% 和 15%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European urology
European urology 医学-泌尿学与肾脏学
CiteScore
43.00
自引率
2.60%
发文量
1753
审稿时长
23 days
期刊介绍: European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.
期刊最新文献
Re: Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1) When Less Is More: The Challenges of Defining Residual Disease Following Neoadjuvant Hormonal Therapy in Prostate Cancer Re: High Sperm Deoxyribonucleic Acid Fragmentation Index Is Associated with an Increased Risk of Preeclampsia Following Assisted Reproduction Treatment Re: A Neoantigen Vaccine Generates Antitumour Immunity in Renal Cell Carcinoma T-Cell Engagers in Prostate Cancer: Promise, Challenges, and the Road Ahead
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1